Vertex Pharmaceuticals Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; the provided text does not give separate Q4 financial results.
Business context
Vertex is a biotechnology company focused on specialty medicines. Its four marketed products treat cystic fibrosis (CF); the company reported that its medicines serve the majority of approximately 88,000 people with CF in North America, Europe and Australia. Revenue remains highly concentrated in CF products, especially TRIKAFTA/KAFTRIO. Pipeline programs include gene editing for sickle cell disease and beta thalassemia, non-opioid pain treatment, APOL1-mediated kidney disease, type 1 diabetes and other indications.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $8.931 billion | $7.574 billion |
| Income from operations | $4.307 billion | $2.782 billion |
| Net income | $3.322 billion | $2.342 billion |
| Diluted earnings per share | $12.82 | $9.01 |
| Operating cash flow | $4.130 billion | $2.644 billion |
| Cash, cash equivalents and marketable securities | $10.779 billion | $7.525 billion |
Revenue grew 18%; operating income rose 55% and net income rose 42%. Approximate operating margin was 48.2% (40.6% in 2021), and net margin was 37.2% (30.9% in 2021), calculated from reported figures. Cost of sales was 12% of net product revenue in both years. FY2022 income tax provision was $910 million, with an effective tax rate of 21.5%, versus 14.2% in 2021.
TRIKAFTA/KAFTRIO revenue increased 35% to $7.687 billion and represented about 86% of net product revenue. U.S. product revenue rose 8% to $5.699 billion; ex-U.S. revenue rose 41% to $3.231 billion. Revenue from SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO declined, primarily as patients switched to TRIKAFTA/KAFTRIO.
Total current assets were $13.235 billion and current liabilities were $2.742 billion, yielding working capital of $10.493 billion and a current ratio of approximately 4.8x. The company reported no borrowings on its $500 million revolving facility at year-end. Balance-sheet liabilities included $471.6 million of finance lease liabilities and $428.1 million of operating lease liabilities; undiscounted future payments were $1.158 billion. The filing does not report conventional funded debt outstanding at year-end.
Material changes and notable items
- Growth was led by international TRIKAFTA/KAFTRIO uptake and continued U.S. performance. Older CF products continued to contract.
- R&D expense increased 31% to $2.540 billion, principally reflecting advancement of clinical programs. SG&A increased 12% to $945 million.
- Acquired in-process R&D expense fell to $116 million from $1.113 billion, largely because 2021 included a $900 million payment to CRISPR related to exa-cel.
- Other expense, net was $165 million in 2022, versus $5 million of income in 2021, primarily reflecting unrealized losses on strategic equity investments. Interest income increased to $145 million from $5 million.
- Operating cash flow increased to $4.130 billion. Investing cash use was $321 million, including the ViaCyte acquisition; financing cash use was $68 million, compared with $1.478 billion in 2021, which included $1.425 billion of share repurchases.
- ViaCyte was acquired for $315 million to support type 1 diabetes programs. Vertex also acquired a complement-targeting portfolio for $60 million. The Entrada collaboration closed in February 2023, after year-end, with approximately $224 million upfront and a $26 million equity investment.
Outlook, management commentary and risks
Management expected 2023 net product revenue to increase, citing continued TRIKAFTA/KAFTRIO performance, younger-patient label expansions and broader access. It expected higher cost of sales in dollars, broadly stable as a percentage of revenue, and higher development and SG&A expenses, including launch preparation for exa-cel. The filing provides no numerical 2023 revenue or earnings guidance.
- Exa-cel: European and U.K. applications were validated; U.S. rolling BLA submission was underway. Vertex expected to complete the U.S. submission by the end of Q1 2023. Approval, safety, manufacturing scale-up and reimbursement remain uncertain; treatment involves cell collection and myeloablative conditioning.
- Pipeline timelines are management expectations, not assurances. Key anticipated milestones included Phase 3 CF triple-combination trial completion by year-end 2023, acute-pain Phase 3 completion in late 2023 or early 2024, and 2023 progress in other programs.
- Principal business risks include dependence on CF revenue, pricing and reimbursement pressure, clinical and regulatory failure, competition, reliance on third-party manufacturing and supply, and the complexity and uncertain acceptance of cell and gene therapies.
- Tax uncertainty increased: unrecognized tax benefits rose to $460 million, primarily associated with intercompany transfer pricing. Changes in tax assessments could affect results.
- Patent disputes involving generic KALYDECO filings were ongoing. The company also disclosed broader uncertainty around CRISPR/Cas9 intellectual-property rights. It stated that it was not subject to material legal proceedings.
- The company reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
- After year-end, the board authorized a $3 billion share repurchase program in February 2023. Vertex has not historically paid cash dividends and did not anticipate doing so in the foreseeable future.
Most important facts for investors to verify
- Whether TRIKAFTA/KAFTRIO growth and international reimbursement can offset declines in older CF products and sustain the company’s concentrated revenue base.
- Actual 2023 results against management’s directional outlook, particularly revenue growth, R&D and launch-preparation spending, and cash generation.
- Regulatory decisions, clinical data and commercialization readiness for exa-cel, including manufacturing capacity, conditioning-related risks and payer coverage.
- Developments in patent litigation and CRISPR/Cas9 intellectual-property proceedings, including potential effects on KALYDECO and exa-cel.
- Changes in rebate estimates and payor mix: FY2022 rebate accruals were $1.291 billion, and net product revenue estimates depend on these assumptions.
- Developments in transfer-pricing audits and the $460 million unrecognized-tax-benefit balance, plus the use and pace of the $3 billion repurchase authorization.